Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.

El Mahdaoui S, Pontieri L, Romme Christensen J, Alabdalridha H, Demirovic M, Harper L K, Illes Z, Jensen H B, Lindengren C D, Mamoei S, et al.